跳至主要内容
临床试验/NCT06970925
NCT06970925招募中1 期

Pilot Study Evaluating Efficacy and Economic Advantage of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care in Patients After Cardiac Surgery

Englewood Hospital and Medical Center2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年6月30日最近更新:

试验速览

阶段
1 期
状态
招募中
入组人数
40
试验地点
2
主要终点
Change in hemoglobin levels

研究概览

简要总结

Primary objective: to evaluate the non-inferiority in terms of improvement of hemoglobin (Hg) levels within 30 days postoperatively between two proposed treatments.

Secondary objective: to evaluate the financial costs associated with Sucrosomial® Iron treatment compared to Iron Sucrose (IV), while demonstrating non-inferiority in the improvement of hemoglobin levels, reduction in transfusion requirements, and reduction of hospital/ICU stay length

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ICU hospitalized patients who underwent non-emergent cardiac surgery
  • Post operative iron deficient or anemic patients (Hb< 12 for both men and women).
  • Patients following the same pre-operative protocol
  • Age >18 years

排除标准

  • Post operative day 1 Hg <9
  • Age >90 years
  • Patients with cancer or other chronic conditions that impair erythropoiesis (e.g. MDS)
  • Stage 3, 4 renal disease
  • Intraoperative transfusion of PRBC

结局指标

主要结局

Change in hemoglobin levels

时间窗: 30 days

Delta change of hemoglobin levels assessed at T1 in Sucrosomial Iron group to demonstrate non-inferiority compared to the Standard of Care.

Financial Cost

时间窗: 30 Days

Financial costs associated with Sucrosomial® Iron treatment compared to Iron Sucrose (IV)

次要结局

  • Transfusion requirements(30 Days)
  • Length of Stay(30 Days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验